October 11, 2011
Takeda Pharmaceutical announced on October 7 that it will discontinue its development in Europe of ramelteon, a treatment of insomnia. Although Takeda Global Research & Development Center (TGRD Europe), Takeda’s wholly owned subsidiary based in London, submitted a marketing authorization...read more